Professional Documents
Culture Documents
Asthma Inhalers
Asthma Inhalers
Inhalers allow people with asthma to lead active lives without fear of an attack. Here's a
rundown of inhaler types, with tips on proper use.
By Mayo Clinic staff
Inhalers have transformed asthma treatment. They enable children and adults with asthma to deliver medicine directly
to their lungs nearly anytime and anywhere. A variety of inhalers are available to help relieve or control asthma
symptoms.
Types of inhalers
Inhalers are hand-held portable devices that deliver medication directly to the lungs. A variety of inhalers exist, but
they basically fall into two categories:
Some metered dose inhalers have counters so that you know how many doses remain. If there is no counter, you
have to track of the number of doses you've used so that you know when the inhaler is out of medication.
The chemical propellant in metered dose inhalers has traditionally been a chlorofluorocarbon (CFC). But after an
international agreement to ban CFCs because they damage the ozone layer, other propellants such as
hydrofluoroalkane (HFA) are now used instead. The dose of medication released by an HFA inhaler may feel softer and
warmer than the dose released by a CFC inhaler. If you're used to a CFC inhaler, it may not seem like a complete dose
— even though the medication is reaching your lungs.
Some people find dry powder inhalers easier to use than the conventional pressurized metered dose inhalers because
hand-lung coordination isn't required. Some models require operating a cocking device that requires dexterity.
Available types include a dry powder tube inhaler, a powder disk inhaler and a single-dose dry powder disk inhaler.
Spacers shouldn't be used with dry powder inhalers.
Inhaler features
Metered dose inhaler Metered dose inhaler with a spacer Dry powder inhaler
Portable and convenient Less portable and convenient, more complex and Portable and convenient
more expensive than a metered dose inhaler
without a spacer
Doesn't require a deep, fast breath Doesn't require a deep, fast breath Requires a deep, fast breath
Accidental exhalation before activation won't Accidental exhalation before activation won't Accidental exhalation before activation will blow
disrupt medication disrupt medication away medication
Hand-actuated models without a spacer require Hand-breath coordination is not critical Hand-breath coordination is not necessary
hand-breath coordination
Can result in large amounts of medication on the Less medication settles on the back of your Can result in large amounts of medication on the
back of your throat and tongue throat and tongue back of your throat and tongue
Minimal or no maintenance required Spacer requires periodic cleaning with soap and Minimal or no maintenance required
water
Some models require you to keep track of how Some models require you to keep track of how It is clear when the device is out of medication
many doses remain many doses remain
Requires shaking and priming Requires shaking and priming, correct use of Single-dose models require loading capsules for
spacer each use
Humidity does not affect medication Humidity does not affect medication High humidity can cause powdered medication to
clump
Short-acting bronchodilators. These medications, including albuterol (Proventil, Ventolin) and pirbuterol (Maxair),
provide immediate relief of asthma symptoms.
Long-acting bronchodilators. These medications relieve asthma symptoms for longer periods of time. They include
salmeterol (Serevent) and formoterol (Foradil).
Corticosteroids. Used long term to prevent asthma attacks, these medications include beclomethasone dipropionate
(Qvar), fluticasone (Flovent), budesonide (Pulmicort), triamcinolone acetonide (Azmacort) and flunisolide (Aerobid).
Cromolyn or nedocromil. These nonsteroidal medications are used long term to prevent inflammation.
Corticosteroid plus long-acting bronchodilator. This medication combines a corticosteroid and a long-acting
bronchodilator (Advair, Symbicort).
Inhalers may come with slightly different instructions. Follow those instructions carefully and ask your doctor for a
demonstration.
If you're unable to use an inhaler, a nebulizer may be an option. Nebulizers are designed for those who can't use an
inhaler, such as infants, young children and those who are seriously ill. The device works by converting medication
into a mist and delivering it through a mask that you wear over your nose and mouth.
Using an inhaler is just one part of your asthma treatment plan, which may also include checking your lung function
with a peak flow meter, eliminating asthma triggers and exercising. But knowing what types of inhalers are available
and how to use them can help you better manage your asthma and get the most from your treatment.
4. Bring the inhaler to your mouth. Place it in your mouth between your teeth and close you mouth around it.
5. Start to breathe in slowly. Press the top of you inhaler once and keep breathing in slowly until you have taken a full breath.
6. Remove the inhaler from your mouth, and hold your breath for about 10 seconds, then breathe out.
If you need a second puff, wait 30 seconds, shake your inhaler again, and repeat steps 3-6. After you've used your MDI, rinse out your mouth and
2. Clean the plastic parts of the device using mild soap and water. (Never wash the metal canister or put it in water.)
3. Let the plastic parts dry in the air (for example, leave them out overnight).
As well:
Keep your reliever MDI somewhere where you can get it quickly if you need it, but out of children's reach.
Show your doctor, pharmacist or asthma educator how you're using your metered-dose inhaler.
Store your MDI at room temperature. If it gets cold, warm it using only your hands.
Never puncture or break the canister, or try to warm it using anything except your hands.
When you begin using an MDI, write the start date on the canister.
Check the expiry date on the MDI before you use it.
If you're having trouble using your MDI, ask your doctor for tips or to recommend another device.
Many doctors recommend the use of a spacer, or a holding device to be used with the MDI.
1. Hold the outer case in one hand. Place the thumb of your other hand in the
thumb grip. Push your thumb as far away from you as it will go. This action opens
the Diskus to expose the lever underneath and locks the mouthpiece into
position.
2. Hold the Diskus in a level position to prevent the medicine from dropping out.
Slide the lever away from you until it clicks. This action loads the dose of
medication. You will see the dose counter decrease by one.
Once you have your DPI loaded, follow these steps to inhale the medication:
1. Turn your head away from the Diskus and breathe out as much air as you
comfortably can.
2. Place the Diskus mouthpiece in your mouth and breathe in as steadily and as
deeply as you can.
3. Remove the Diskus from your mouth and hold your breath for up to 10 seconds.
4. Close the Diskus by placing your thumb in the thumb grip and sliding the grip back
toward you, over the mouthpiece. This action resets the inhaler so it is ready to
use for the next treatment.
1. Turn your head away from the inhaler and breathe out as much air as you
comfortably can.
2. Place the device in your mouth and breathe in as quickly and as deeply as you can.
3. Hold your breath for up to 10 seconds.
4. Take the DPI away from your mouth and exhale slowly.
5. If more than one dose is prescribed, load another dose, and repeat steps 1
through 5 for each dose.
6. When your treatment is complete, replace the white cover and twist it completely
to close.
The Diskus (figure 1) contains 60 doses of medication (Advair, Flovent, or Serevent are the brand names of the
medication that may be prescribed for you). It has a dose indicator that counts down the number of doses as you use
them. Doses 5 through 0 are in red to alert you to refill your prescription. When the "0" appears in the dose indicator,
throw away the Diskus and begin a new one.
1. Hold the Diskus in your left hand. Place the thumb of your right hand in the
thumb grip. Push your thumb as far away from you as it will go. This action
opens the Diskus to expose the lever underneath.
2. Slide the lever away from you until it clicks. This action loads the dose of
medication. You will see the dose counter decrease by one.
3. Turn your head away from the Diskus and breathe out as much air as you comfortably can.
4. Place the Diskus mouthpiece in your mouth and breathe in as steadily, and as deeply as you can.
7. Close the Diskus by placing your thumb in the thumb grip and slide the grip back toward you, as far as it will go.
This action resets the inhaler so it is ready to use for the next treatment.
8. If more than one dose is prescribed, repeat steps 1 through 7 for each dose.
nhaler Types
There are many different inhalers used to deliver IPAs. Most people have seen someone using a "puffer" to alleviate
asthma symptoms. The technical term for such puffers is "pressurized metered dose inhaler" or "propellant metered
dose inhaler", usually abbreviated as pMDI or simply MDI. A sketch of a typical such device is shown below.
pMDIs are the most commonly used inhaler worldwide, and have been used since the mid 1950s. The aerosol is
created when a valve is opened (usually by pressing down on the propellant canister), allowing liquid propellant to
spray out of a canister (in a manner somewhat similar to everyday aerosol spray cans), involving a complex process
called cavitation. The drug is usually contained in small particles (usually a few millionths of a meter in diameter)
suspended in the liquid propellant, but in some formulations the drug is dissolved in the propellant. In either case, the
propellant evaporates rapidly as the aerosol leaves the device, resulting in small drug particles that are inhaled. Prior
to the mid 1990s, pMDIs used various chlorofluorocarbons (CFCs) as their propellant, but with the elimination of
CFCs in industry due to ozone depletion concerns, the propellants in new pMDIs typically use hydrofluoroalkanes
(HFAs), which do not result in ozone depletion.
Add-on devices (spacers, holding chambers and other modifications) are sometimes used with pMDIs (particularly in
young children) to remove the difficulty some patients have with coordinating inhalation with firing the pMDI spray.
Such add-on devices can also reduce the amount of drug depositing in the mouth and throat.
Although pMDIs are the most common type of modern day inhaler, they are not the oldest. This honour goes to
nebulizers, which have been around in one form or another for more than a century. Nebulizers produce a mist of
drug-containing water droplets for inhalation. They are usually classified into two types: electronic nebulizers and jet
nebulizers. Jet nebulizers are more common due to their lower cost, and use a source of pressurized air to blast a
stream of air through a drug-containing water reservoir, producing droplets in a complex process involving a
viscosity-induced surface instability that leads to nonlinear phenomena in which surface tension and droplet breakup
on baffles play a role. In contrast, electronic nebulizers produce droplets by mechanical vibration of a plate or mesh.
In either type of nebulizer, the drug is usually contained in solution in the water in the nebulizer and so the droplets
being produced contain drug in solution. However, for some formulations (notably Pulmicort) the drug is contained in
small particles suspended in the water, which are then contained as particles suspended inside the droplets being
produced. A schematic of a typical nebulizer is shown below.
The third major type of inhaler is the dry powder inhaler, abbreviated as DPI. In DPIs the aerosol is a powder,
contained within the device until it is inhaled. The therapeutic drug is manufactured in powder form as small powder
particles (usually a few millionths of a meter, or micrometers, in diameter). In many DPIs the drug is mixed with
much larger sugar particles (usually lactose monohydrate), that are typically 50-100 micrometers in diameter. The
much smaller drug particles attach to these excipient particles. The increased aerodynamic forces on the lactose/drug
agglomerates improve entrainment of the small drug particles upon inhalation, in addition to allowing easier filling of
small individual powder doses. Upon inhalation, the powder is broken up into its constituent particles with the aid of
turbulence and/or mechanical devices such as screens or spinning surfaces on which particle agglomerates impact,
releasing the small, individual drug powder particles into the air to be inhaled into the lung. The sugar particles are
intended to be left behind in the device and in the mouth-throat.
Although pMDIs, DPIs and nebulizers are the three major types of inhalers currently on the market today, new inhaler
designs are continually being invented and several novel designs are making their way through the regulatory
approval process, so that in the future we may see inhalers that do not readily classify into one of the three traditional
inhaler types mentioned above.
When the lung is the target for the aerosol (either because the intent is to treat the lung surface or to get the drug into
the blood through the capillaries via the alveoli) the inhaled aerosol must consist of particles in a certain size range.
This is because particles larger than a certain size tend to simply land in the mouth and throat and mostly do not make
it into the lung (like a big truck travelling too fast around a corner, they have too much mass to make it around the
bends in the convoluted path through the mouth and throat). Particles somewhat smaller than a certain size tend to get
inhaled and then exhaled right back out, while very small particles usually can't be made in high enough numbers to
give high enough dosages. Thus, IPAs are usually designed to produce drug particles each having the incredibly small
mass of between approximately 1 trillionth and 100 trillionths of a gram. For particles with densities near that of
water, this corresponds to particle diameters of a few millionths of a meter (i.e. a few micrometers). For example, the
figure below shows the probability that inhaled droplets of different diameters will deposit in the mouth-throat
("extrathoracic"), tracheobronchial and alveolar regions of the lung for a particular aerosol used in treating asthma (the
curves in the figure below will be different for a different aerosol and cannot be used to evaluate other aerosols than
the one shown, particularly since the aerosol shown undergoes drug specific evaporation in the lung).
Although specific size ranges are often quoted as being ideal for IPAs (e.g. 1-5 micrometers in diameter), significant
amounts of particles outside this size range can deposit in the lung, so that these size ranges should not be viewed as
strict criteria. This is partly because the speed of the inhaled air plays a significant role in determining what size of
particles will deposit where in the respiratory tract (so that someone breathing very slowly may cause larger particles
to make it deeper in the lung than someone inhaling very rapidly). In addition, the filtering curves for particle
deposition are slowly varying functions of particle size, and do not give ideal "bandpass" filtering of particle size, as is
clearly seen in the figure above. The reader can use our Deposition Calculator to examine how different parameters
affect aerosol deposition in the respiratory tract. Finally, droplet evaporation or condensation can be different for
different aerosols and result in different deposition patterns with different aerosols.
Scientists and engineers must cope with several factors that make designing an IPA device quite difficult. One of the
main challenges with IPAs is producing such small particles - it is not easy to efficiently produce drug particles that
have a mass between 1 and 100 trillionths of a gram in a device that be carried around easily! Even if a process is
developed that can produce such small drug particles for one particular drug, it may work differently, or not work
well, for a different drug. Unfortunately, no general theory is available to predict the behaviour of different drugs in
different devices, so the research and development process must be revisited for each drug under consideration, a
time-consuming and labor intensive process.
Another challenge is caused by the fact that everyone inhales differently. Thus, the speed of the air that an inhaled
pharmaceutical aerosol (IPA) is exposed to is different for everyone. This presents some interesting challenges. For
example, for certain dry powder inhalers, this requires trying to design the powder so that people inhaling either
slowly or quickly both inhale similar amounts of powder from the device. Inhaled air speed can also affect where
particles deposit in the respiratory tract, as can clearly be seen by using our Deposition Calculator to examine the
effect of different flow rates on aerosol deposition in the respiratory tract.
A second complicating factor is caused by differences in the geometry of people's mouth-throat airway passages, with
some people having very sudden bends that cause many particles to deposit in the mouth-throat while others have a
relatively "smooth" mouth-throat passage with much less mouth-throat deposition. This can cause variability in the
dose reaching the lung between different patients. Recent work by us allows accurate person specific prediction of this
variability, allowing us to overcome one of the major factors responsible for intersubject variability with inhaled
pharmaceutical aerosols. A further complication is added by the differing effects of device mouthpieces on mouth-
throat geometry and their effect on the fluid mechanics in the mouth-throat (small diameter mouthpieces that have
been commonly used in the past have been shown by us to cause high mouth-throat deposition due to a high speed jet
of air impacting in the mouth). There are also differences in the lung geometry between individuals. Mouth-throat
geometry, mouthpiece diameter and lung volume effects are included in our Deposition Calculator. Finally, different
disease states can also result in differences in where IPAs deposit in the lungs of different individuals.
For drug carried by inhaled water droplets (such as are produced by nebulizers), the humidity of the air being inhaled
can cause differing amounts of droplet evaporation and also give rise to variations in where the drug deposits in the
lung. In fact, evaporation of nebulized aerosols leads to one of the most commonly made mistakes when measuring
nebulized aerosols with a measurement device called a cascade impactor. Users unfamiliar with nebulized aerosols
often mistakenly mix the nebulized aerosol with room air during sizing, or else allow the nebulized aerosol to be
warmed to room temperature inside the cascade impactor, both of which can lead to significant undersizing of the
aerosol (and incorrect assumptions regarding where in the lung the aerosol will deposit).
These are just a few of the challenges that need to be considered with IPAs. Much research goes into overcoming
these, as well other challenges not mentioned here. Indeed, the field of IPAs is relatively unexplored in comparison
with traditional engineering fields. The Aerosol Research Laboratory of Alberta is one of several laboratories that is
helping to explore this interesting and important area.
Oxeze® turbuhaler
Manufacturer: Form:
AstraZeneca breath-activated dry powder inhaler
Canada Inc.
Route:
Generic Name: oral inhalation
formoterol
fumarate
Why is it prescribed?
Formoterol is used to prevent bronchospasm associated with asthma and other pulmonary
disorders. It is indicated for people using optimal doses of an inhaled anti-inflammatory drug
but still experiencing regular or frequent breakthrough symptoms (e.g. coughing and
wheezing) which require the use of rescue bronchodilators.
Side Effects
Along with its needed effects, formoterol may cause some unwanted or undesirable effects.
Often, formoterol users who use their medication properly, never experience any unwanted
effects. The severity and duration of these effects are dependant on many factors including
duration of therapy, dose, route of administration and individual response. Common:
headache
tremor
dizziness
Uncommon:
agitation
difficulties in sleeping
Rare:
Check with your pharmacist or doctor if mild effects persist and become bothersome or if
more severe effects occur.
Maximum benefit cannot be achieved unless the inhalation device is used correctly. Even if
you have used this device before, you should have your technique reassessed by your
pharmacist and read the patient instructions that are provided with each inhaler.
Formoterol should be inhaled twice daily, regularly in the morning and at night. It is important
not to use formoterol more often than twice daily or to exceed the number of inhalations
prescribed by your doctor. Doing so increases the risk of potentially serious unwanted effects.
An inhalation of formoterol begins to work in 1 to 3 minutes and the effects last for up to 12
hours. Because of its long duration of action, it should never be used for
acute asthma symptoms (e.g. wheezing, coughing, shortness of breath). Use a short-
acting bronchodilator (e.g., salbutamol or terbutaline) if you experience these symptoms
between the two daily doses of formoterol.
Formoterol is not a replacement for inhaled anti-inflammatory medications (e.g.
corticosteroids). You must continue to use an inhaled anti-inflammatory at the dose that you
and your doctor have determined is best for you.
Using two or more inhaled medications can be confusing. Ensure that you know the purpose
of each inhaler and when it should be used.
Formoterol is intended for long-term treatment. It should not be started in people whose
asthma is worsening or unstable.
If your rescue medication isn't working as well as it usually does and/or you need more
frequent doses to control breakthrough symptoms, your asthma may be worsening. Your
condition should be reassessed by your doctor immediately.
Drug Interactions: Be sure to tell your doctor and pharmacist about any prescription and over-
the-counter medications you are taking in order to avoid any potential drug interactions. The
following drugs and drug classes have been known to interact with formoterol:
prednisone
allergy to formoterol
diabetes
heart disease
Use in pregnancy: Consult your doctor or pharmacist if you suspect you are pregnant or if you
plan to become pregnant.
Use while breastfeeding: Consult your doctor or pharmacist before using formoterol while
breastfeeding.
Use in children: Use of formoterol has not been adequately evaluated in children less than 6
years old.
Patient Information
Before using Oxeze® for the first time, be sure you understand how to use the turbuhaler: (dry
powder inhaler). Your doctor or pharmacist will demonstrate the proper method of loading
and inhaling Oxeze® but you should also read and keep the package insert which comes with
each inhaler. To ensure that you are getting maximum benefit from Oxeze® ask your
pharmacist to assess your inhalation technique.
Do not shake Oxeze® before use.
When the inhaler is loaded, your dose will be lost if the inhaler is accidentally dropped,
shaken, or if you breathe into the inhaler. If this happens, reload the inhaler before using.
Oxeze® turbuhaler does not contain an aerosol propellant. You draw the powder into your
lungs with your breath. Therefore, it is important to inhale sharply and deeply through the
mouthpiece when using the inhaler. Since only a very small amount of powder is inhaled with
each dose, you may not taste or feel anything when you use the inhaler. As long as you are
using the inhaler correctly, you will be receiving the prescribed amount of Oxeze®.
Oxeze® should not be used more often than twice a day. If your forget a dose, take it as soon
as possible. But, if it is almost time for your next dose, do not take the missed one, just resume
your regular schedule. Doubling up on your regular dosage could increase the chance of
serious unwanted effects.
Each turbuhaler contains 60 doses. When a red mark appears in the little window under the
mouthpiece there are approximately 20 doses remaining. You should refill your prescription at
this time.
When the red mark reaches the bottom of the window, all the doses of Oxeze® have been
used. The drying agent in the inhaler will still make a rattling sound if the inhaler is shaken.
This does not indicate that there is active ingredient remaining in the inhaler.
Oxeze® turbuhaler will not operate properly if it is exposed to moisture. Never use water or
other fluids to clean the inhaler. Always replace the cap on the inhaler after using. Store at
room temperature (15 to 30 degrees Centigrade) in a dry place.
Clean the turbuhaler once weekly using a clean, dry cloth.
The usual maintenance dose of asthma in adults is 6 to 12 mcg twice daily, at 12 hour
intervals. In adults, the maximum recommended daily dose is 48 mcg. The usual maintenance
dose of asthma in children between the ages of 6 to 16 years is 6 to 12 mcg twice daily, at 12
hour intervals. In children, the maximum recommended daily dose is 24 mcg.
asthma
COPD
emphysema (COPD)
A spacer is a large chamber which is fitted to an inhaler. An asthma spacer is a device used by an asthmatic to
increase the effectiveness of an asthma inhaler.
Spacers are specially designed plastic or metal tubes that fit an inhaler on one end, while the patient breathes
normally on the other end. Some spacers utilize a collapsing bag design to provide visual feedback that successful
inspiration is taking place.
In order to properly use an inhaler without a spacer, one has to co-ordinate a certain number of actions in a set order
(pressing down on the inhaler, breathing in deeply as soon as the medication is released, holding your breath,
exhaling), and not all patients are able to master this sequence. Use of a spacer avoids such timing issues. Spacers
slow down the speed of the aerosol coming from the inhaler, meaning that less of the asthma drug impacts on the
back of the mouth and more gets into the lungs. Because of this, less medication is needed for an effective dose, and
there are fewer side effects from corticosteroid residue in the mouth.
Valves on the spacers cause the patient to breathe the contents of the spacer, but exhalation goes out into the air.
The problem of co-ordinating an inspiration with the press of an inhaler is avoided, making use easier for children
under 5 and the elderly. It also makes asthma medication easier to deliver during an attack.
Polystyrene cups or large plastic bottles can be used as spacers for children in an emergency.
Turbuhaler®
Diskus®
Diskhaler®
Rotahaler®
Nebuliser
How to use a metered dose inhaler – if you don't have a spacing chamber
1. remove the cap from the mouthpiece and shake the inhaler
2. breathe out to the end of a normal breath
3. position the mouthpiece end of the inhaler about 2-3 finger widths from your
mouth
4. open your mouth widely & tilt your head back slightly, or close your lips
around the mouthpiece
5. start to breathe in slowly, then push down once on the container – this will
spray medication into your mouth
6. continue breathing in slowly until your lungs are full
7. once you have breathed in fully, hold your breath for 10 seconds or as long as you can
8. breathe out normally
9. if you need a second puff, wait one minute and repeat these steps
10. rinse you mouth out & gargle with water after you use your inhaler, to prevent a local yeast infection (thrush) in your mouth,
and hoarseness in your throat.
How to keep track of how much is left in your metered dose inhaler
People have a hard time figuring out how much medicine is left in their inhaler. Inhalers have two ingredients in them- your medicine,
which helps you breathe, and a propellant, which is there to push the medicine out, but which is not medicine itself. If you have some
fluid left in your inhaler, you just can't tell what in it- it could be medicine and propellant, or it could just be propellant. If it's just
propellant, and you take it, you won't get any benefit, and it could actually make your breathing worse.
Sometimes people try to shake the inhaler, float it in water, or taste it to see how much is left. None of these methods work. The only
way to tell how many doses are left in the inhaler is to keep track of the doses you've taken by writing them down. You can tape
a piece of masking tape to the outside of the inhaler, and mark a line every time you take a dose. Or you can keep a notebook and pen
in a bag with your inhaler, and record each dose in the notebook.
Back to Top
Remove the cap and shake the inhaler to mix the contents.
Place the inhaler mouthpiece in the inhaler adapter of the Aero Chamber®.
Place the mask over your mouth and nose, making sure it is well sealed.
Press the canister down to spray one puff of medication into the AeroChamber®.
If more than one puff is prescribed, repeat the procedure (do not spray more than one puff at a time into the
AeroChamber®).
Back to Top
Diskus® (dry powder inhaler)
A Diskus® consists of a plastic device containing powdered medication. A Diskus® is breath activated. This means when you inhale,
the Diskus® automatically releases the medication. When inhaled correctly, the medication has a better chance to reach the small
airways. This increases the medication's effectiveness.
1. Take the Diskus® out of the foil wrapper. Once the foil wrapper is opened the Diskus® must be used within two months.
2. Hold the Diskus® level with one hand.
3. Place the thumb of the other hand on the thumbgrip.
4. Push your thumb away from you until the Diskus® clicks. This will open the Diskus® so you can see the mouthpiece.
5. Hold the Diskus® level and slide the lever away from you until the Diskus® clicks. This will load the medication. Keep the
Diskus® level so you don't loose the medication. Hold the Diskus® level and away from your mouth and gently breathe out.
Never exhale into to Diskus®.
6. Seal your lips around the mouthpiece.
7. Inhale rapidly and deeply. Continue to take a full, deep breath.
8. Hold your breath for up to ten seconds. This allows the medication time to deposit in the airways.
9. Resume normal breathing.
10. Close the Diskus® by placing your thumb on the thumpgrip. Pull your thumb toward you until the discus clicks. The
mouthpiece will be hidden and the lever will be reset.
11. If the medicine you are taking contains a corticosteroid, rinse your mouth out & gargle with water after you use it, to prevent a
local yeast infection (thrush) in your mouth, and hoarseness in your throat.
Back to Top
Back to Top
Diskhaler® (dry powder inhaler)
Diskhaler® is a device you load with a small plastic disk. The disks contain several small pouches (blisters), each
holding one dose of medication. Each time you need a dose, the Diskhaler® punctures (bursts) a pouch of the
medication on the disk, so you can inhale it.
1. Remove the cover and check that the Diskhaler and mouthpiece are clean.
2. If a new medication disk is needed, pull the corners of the white cartridge out as far as it will go, then press the ridges on the
sides inwards to remove the cartridge.
3. Place the new medication disk on the white rotating wheel, numbers facing up. Slide the cartridge all the way back in.
4. Pull the cartridge all the way out, then push it all the way in until you can see the highest number on the medication disk in
the indicator window.
5. With the cartridge fully inserted, and the device kept flat, raise the lid as far as it goes, to pierce both sides of the medication
blister.
6. Move the Diskhaler® away from your mouth and blow out all of your breath.
7. Place the mouthpiece between your teeth and lips, making sure you do not cover the air holes on the mouthpiece. Inhale as
quickly and deeply as you can.
8. Take the Diskhaler® away from your mouth and holding your breath for about 10 seconds.
9. Breathe out slowly.
10. If you need another dose, pull the cartridge out all the way and then push it back in all the way. This will move the next blister
into place. Repeat steps 5 through 9.
11. After you have finished using the Diskhaler®, put the cap back on.
12. If your Diskhaler® contains a corticosteroid medicine, rinse you mouth out & gargle with water after you use it, to prevent a
local yeast infection (thrush) in your mouth, and hoarseness in your throat.
Top of page
1. To load the Rotahaler®, hold it by the mouthpiece and twist the barrel in one direction until it stops turning.
2. Holding the Rotahaler® vertically, press the clear end of the Rotacap? into the capsule insert hole (the top of the Rotahaler®
should be level with the top of the hole).
3. Holding the Rotahaler® vertically, with the white dot up, twist the barrel in the opposite direction until it stops - the Rotahaler®
is now loaded.
4. Breathe out.
5. Place the mouthpiece in your teeth and close your lips around it.
6. Tilt your head back slightly.
7. Breathe in deeply and forcefully through your mouth.
8. Hold your breath and remove the Rotahaler®: from your mouth.
9. Hold your breath for 10 seconds or as long as you can.
10. Breathe out slowly.
11. To ensure you have inhaled the full dose, replace the Rotahaler? in your mouth and repeat the above steps.
12. Discard the empty Rotacap® shell.
13. Sometimes 2 or 3 forceful inhalations are needed to make sure you have inhaled the full dose.
14. If a second Rotacap® is prescribed, repeat the procedure.
15. If your Diskhaler® contains a corticosteroid medicine, rinse you mouth out & gargle with water after you use it, to prevent a
local yeast infection (thrush) in your mouth, and hoarseness in your throat.
Back to Top
Doctors often ask people with chronic lung disease to take peak flow
readings every day, and by recording their readings. Sometimes people use an asthma diary card to record their readings. Taking your
peak flow regularly can help you recognize changes in your airflow, and can help you catch exacerbations before they get out of control.
You can buy a peak flow meter at your drugstore; they cost between $20.00 - $70.00.
A peak flow meter measures the rate of airflow, or how fast air is able to pass through the airways. The narrower your airways, the
slower the rate will be. Peak flow monitoring is one useful tool to measure airway obstruction (blockage).
Ask you doctor, certified asthma educator, or pharmacist to show you how to use your peak flow meter. Ask them how to understand
what your peak flow readings mean. Find out how you should change your treatment and medication depending on what the peak flow
meter readings are.
Use the same peak flow meter consistently; peak flow meters might take different readings, and using more than one device can
confuse the results.
Top of page
Nebuliser
Nebulisers are medical devices that deliver medicine as a vapour for people to inhale.
1. Find a location where you can sit comfortably for 10-15 minutes. Plug in the compressor.
2. It is very important to get specific written instructions if you are mixing your own nebulized treatments. Mix the medication as
directed, or empty the prepared unit dose vials (UDVs) into the nebulizer. Do not mix different types of medications without
permission from your doctor or pharmacist.
3. Assemble the mask or mouthpiece and connect the tubing from this to the port on the compressor.
4. Sit in an upright position, making sure you are comfortable. Put the mask over your nose and mouth (make sure it fits
properly so the mist doesn't flow up into your eyes); OR, if you are using a mouthpiece, put it into your mouth.
5. Turn on the compressor.
6. Take slow, deep breaths. If possible, hold your breath for 10 seconds before slowly exhaling.
7. Continue until the medication chamber is empty.
This information is not intended to replace the medical advice of your doctor or health care provider. Please
consult your health care provider for advice about a specific medical condition.
Dry powder inhalers are becoming more common, in part because they do not use the "CFC" propellant that used to
be in all MDIs. (CFCs damage the ozone and will be phased out of MDIs in the next few years.) Dry powder inhalers
are as effective as MDIs -- in fact, some may prove to be slightly more effective.
Naturally, there are several disadvantages. If the patient exhales directly toward the device, the powder can be blown
out. Also, much of the powder ends up in the mouth, which can cause unwanted side effects -- this is similar to what
happens when a patient puts an MDI directly into their mouth. As with MDIs, it is recommended that you wash your
mouth after administering the drug.
Figure 1. Cross-section of Easyhaler® - a new generation, multidose dry powder inhaler.
Figure 1. Easyhaler® multidose dry powder inhaler.
MDI Technology for Inhalation and Nasal/Buccal Drug Delivery
Metered Dose Inhalers (MDIs), first introduced in the 1950s as a novel therapy for treating respiratory diseases like asthma and chronic
obstructive pulmonary disorder (COPD), are important medicines.
Asthma often occurs in the form of life threatening, acute attacks which need immediate treatment. Therefore, patients always have to
carry with them the necessary active substance in the small pocket-sized dispensers, the metered dose inhalers. The dispenser contains
a mixture consisting of the propellant and the pharmaceutical active substance dissolved or suspended in the liquefied propellant and
sometimes with further excipients such as cosolvents and /or surfactants added in very small amounts. When the patient actuates the
MDI, the propellant immediately evaporates at ambient conditions and produces a fine spray, the aerosol.
The incidence of asthma in developed countries is around 5 to 8% of the population and increasing at an average rate of around 5% per
year. Asthma and COPD are particulary prevalent amongst children, as the incidence in this group now approaches 15% in Western
Europe.
Worldwide, at least 300 million people suffer from asthma, and a comparable number from COPD. A minimum of 50 to 60 million
patients therefore rely on metered dose inhalers. There is international consensus that the primary treatment of these diseases should
be via inhalation – with the MDI remaining the dominant inhaled delivery system in most countries and for all categories of drugs.
Major advantages of MDIs over oral therapy and stationary nebulisers are the ease of use, its reliability, its self-contained power source,
the low costs per unit, and most important, the high patient compliance, including use by young children.
The MDI is a pocket-sized, hand-held, pressurised multiple-dose inhalation delivery system. It delivers small, precisely measured
therapeutic doses, greatly minimising the risk of adverse side effects. Unlike most nebulisers, it is portable and convenient to use.
The function of an MDI is the consistent delivery of the same amount of medication in the form of an aerosol. This allows deposition in
the passageways of the lungs.[36]
MDIs are used for the inhalation of all commonly prescribed respiratory medication and account for 70% of all inhalation therapy in the
world’s fifteen largest patient populations.[36]
A broad range of medications worldwide has been developed for the treatment of asthma, chronic obstructive pulmonary disorder
(COPD) and respiratory infection.
Already available as HFA-MDI medications are e.g. disodium cromoglycate, nedocromil, reproterol, isoproterol in combination with
atropinmethylbromide and dexamethasone, procaterol, salmeterol, salbutamol, beclomethasone, fenoterol, ipratopium bromide,
fluticasone, and combinations thereof.[35]
HFA MDIs are more efficient than CFC MDIs because virtually every aspect of MDIs has improved in recent years.
Moreover, MDIs are capable of systemic delivery, including proteins and peptides, and are also developed for nasal and buccal drug
delivery.
Diseases currently targeted for pulmonary or buccal drug delivery include, among others, diabetes, Alzheimer’s, influenza, multiple
sclerosis, pain disease, cystic fibrosis and osteoporosis.
Fig. 11: HFA 227 propelled MDI Product “Stomerin” launched by Fujisawa in September 2001 in Japan
List of applications
Refrigerants (Solkane)
Pharmaceuticals